Гиполипидемическая терапия в особых ситуациях
DOI:
https://doi.org/10.34687/2219-8202.JAD.2024.03.0008Аннотация
Ведение пациентов с нарушениями липидного обмена зачастую затруднено наличием сопутствующей патологии и состояний, не позволяющих применять классические схемы диагностики, стратификации риска и подходов к лечению. В рамках данного обзора обсуждены сложные вопросы ведения пациентов с дислипидемиями в особых ситуациях.
Скачивания
Библиографические ссылки
Anitchkow N, Chalatow S. Über die Veränderungen der Kaninchenaorta bei experimenteller Cholesterinsteatose. Zentrabl Aleg Pathol Anat.1913;24:1-9.
Goldstein JL, Brown MS. Familial hypercholesterolemia: Identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973;70(10):2804-8. doi: 10.1073/pnas.70.10.2804.
Lan NSR, Bajaj A, Watts GF, Cuchel M. Recent advances in the management and implementation of care for familial hypercholesterolaemia. Pharmacol Res. 2023;194:106857. doi:10.1016/j.phrs.2023.106857.
Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277-2291. doi: 10.1093/eurheartj/ehad197.
Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 million Subjects. J Am Coll Cardiol. 2020;75(20):2553-2566. doi: 10.1016/j.jacc.2020.03.057.
Meshkov AN, Ershova AI, Kiseleva AV, Shalnova SA, Drapkina OM, Boytsov SA, On Behalf of The Fh-Esse-Rf Investigators. The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. J Pers Med. 2021;11(6):464. doi: 10.3390/jpm11060464.
Brandts J, Ray KK. Familial Hypercholesterolemia: JACC Focus Seminar 4/4. J Am Coll Cardiol. 2021;78(18):1831-1843. doi: 10.1016/j.jacc.2021.09.004.
Ezhov M.V., Kuharchuk V.V., Sergienko I.V., Alieva A.S., Anciferov M.B., Ansheles A.A. Dislipidemia. Guidelines 2023. Russian cardiological journal. 2023;28(5):250-297. (Ежов М.В., Кухарчук В.В., Сергиенко И.В., Алиева А. С., Анциферов М.Б., Аншелес А.А., Арабидзе Г. Г., Аронов Д. М., Арутюнов Г. П., Ахмеджанов Н. М., Балахонова Т. В., Барбараш О. Л., Бойцов С. А., Бубнова М. Г., Воевода М. И., Галстян Г. Р., Галявич А. С., Горнякова Н.Б., Гуревич В. С., Дедов И. И., Драпкина О. М., Дупляков Д. В., Ерегин С. Я., Ершова А.И., Иртюга О.Б., Карпов Р.С., Карпов Ю.А., Качковский М.А., Кобалава Ж. Д., Козиолова Н. А., Коновалов Г. А., Константинов В. О., Космачева Е. Д., Котовская Ю.В., Мартынов А. И., Мешков А. Н., Небиеридзе Д.В., Недогода С.В., Обрезан А.Г., Олейников В.Э., Покровский С.Н., Рагино Ю.И., Ротарь О.П., Скибицкий В.В., Смоленская О.Г., Соколов А.А., Сумароков А.Б., Ткачева О. Н., Филиппов А.Е., Халимов Ю.Ш., Чазова И.Е., Шапошник И. И., Шестакова М.В., Якушин С. С., Шляхто Е.В. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):250-297.) doi:10.15829/1560-4071-2023-5471. EDN YVZOWJ
Chubykina U.D., Ezhov M.V., Rozhkova T.A., Tamaeva B.M., Sokolov A.A., Ershova A.I. Five-year observation period of patients with homo- and heterozygous familial hypercholesterolemia in the RENAISSANCE registry. Atherosclerosis and dyslipidemia. 2023;1(50):5-18. (Чубыкина У.В., Ежов М.В., Рожкова Т.А., Тамаева Б.М., Соколов А.А., Ершова А.И., Мешков А.Н., Михайлина В.И., Блохина А.В., Лимонова А.С., Копылова О.В., Шапошник И. И., Генкель В.В., Гуревич В.С., Уразгильдеева С.А., Трегубов А.В., Музалевская М.В., Воевода М.И., Тимощенко О.В., Шахтшнейдер Е.В., Рагино Ю. И., Леонтьева И.В., Егоров Л.В., Захарова И.Н., Пшеничникова И.И., Садыкова Д.И., Сластникова Е.С., Галимова Л.Ф., Космачева Е.Д., Намитоков А.М., Алиева А.С., Галявич А. С., Ким З.Ф., Корнева В.А., Кузнецова Т.Ю., Филиппов А.Е., Туктаров А.М., Воробьев А.С., Астраханцева И.Д., Богданов Д.Ю., Качковский М.А., Егорова А.В., Константинов В.О., Серебреницкая М., Зафираки В.К., Бизяева Н.Н., Андросюк Н.Г., Киселева М.А., Григорьева Ю.Г., Кореннова О., Юхина Ю.Е., Девятова М.Д., Иванова О.Н., Васильев П.А., Авдеева И.В., Олейников В.Э., Воробьева Ю.А., Ермакова Ю.А., Муха Н.В., Зайцев Д.Н., Зыков М.В., Исаева А.В., Петелина Т.И., Микова Е.В. Пятилетний период наблюдения за пациентами с гомо- и гетерозиготной семейной гиперхолестеринемией в регистре РЕНЕССАНС. Атеросклероз и дислипидемии. 2023;1(50):5-18.) DOI: 10.34687/2219-8202.JAD.2023.01.0001.
EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021 Nov 6;398(10312):1713-1725. doi: 10.1016/S0140-6736(21)01122-3.
Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H et al. Homozygous Familial Hypercholesterolaemia International Clinical Collaborators. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022;399(10326):719-728. doi: 10.1016/S0140-6736(21)02001-8.
Ray KK, Ference BA, Séverin T, Blom D, Nicholls SJ, Shiba MH, et al. World Heart Federation Cholesterol Roadmap 2022. Glob Heart. 2022;17(1):75. doi: 10.5334/gh.1154.
Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429-434. doi: 10.1038/s41586-021-03534-y.
Kenet G, Lutkhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 2010; 121:1838–1847. doi: 10.1161/CIRCULATIONAHA.109.913673.
Kamstrup PR, Nordestgaard BG. Elevated lipoprotein (a) levels, LPA risk genotypes and increased risk of heart failure in the general population. JACC Heart Fail 2016;4:78–87. doi: 10.1016/j.jchf.2015.08.006. Epub 2015 Dec 2. PMID: 26656145.
Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arterioscler Thromb Vasc Biol. 2020;40(1):255-266. doi: 10.1161/ATVBAHA.119.312951. Epub 2019 Oct 3. PMID: 31578080.
Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res 2016;57:1953–1975. doi: 10.1194/jlr.R071233. Epub 2016 Sep 27. PMID: 27677946; PMCID: PMC5087876.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–188.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361. PMID: 36036785; PMCID: PMC9639807.].
O’Donoghue M.L., Fazio S., Giugliano R.P. Lipoprotein (a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483–1492. DOI: 10.1161/CIRCULATIONAHA.118.037184
Warden BA, Guyton JR, Kovacs AC, Durham JA, Jones LK, Dixon DL, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from National Lipid Association. J Clin Lipidol. 2023;17(1):19-39. doi: 10.1016/j.jacl.2022.09.001. Epub 2022 Sep 11. PMID: 36115813.
Stock J. Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group. Atherosclerosis. 2015;242(1):346-50. doi: 10.1016/j.atherosclerosis.2015.06.049. Epub 2015 Jul 6. PMID: 26253793.
Penson PE, Bruckert E, Marais D, Reiner Ž, Pirro M, Sahebkar A, et al. International Lipid Expert Panel (ILEP). Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle. 2022;13(3):1596-1622. doi: 10.1002/jcsm.12960.
Bannay A, Bories M, Le Corre P, Riou C, Lemordant P, Van Hille P, et al. Leveraging National Claims and Hospital Big Data: Cohort Study on a Statin-Drug Interaction Use Case. JMIR Med Inform. 2021;9(12):e29286. doi: 10.2196/29286.
Stam-Slob MC, Visseren FL, Wouter Jukema J, van der Graaf Y, Poulter NR, Gupta A, et al. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clin Res Cardiol. 2017;106(1):58-68. doi: 10.1007/s00392-016-1023-8. Epub 2016 Aug 23. PMID: 27554244; PMCID: PMC5226996
Rosada A, Kassner U, Weidemann F, König M, Buchmann N, Steinhagen-Thiessen E, et al. Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study. Lipids Health Dis. 2020;19(1):92. doi: 10.1186/s12944-020-01277-9. PMID: 32410691; PMCID: PMC7227351.
Fulcher J, Mihaylova B, O'Connell R, Emberson J, Blackwell L, Reit C et al. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomized controlled trials. Lancet. 2019;393(10170):407-415. doi: 10.1016/S0140-6736(18)31942-1. PMID: 30712900; PMCID: PMC6429627.
Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomized controlled trials. Lancet. 2020;396(10263):1637-1643. doi: 10.1016/S0140-6736(20)32332-1. Epub 2020 Nov 10. PMID: 33186535; PMCID: PMC8015314.
Savarese G, Gotto AM Jr, Paolillo S, D'Amore C, Losco T, Musella F, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62(22):2090-9. doi: 10.1016/j.jacc.2013.07.069. Epub 2013 Aug 28. Erratum in: J Am Coll Cardiol. 2014 Mar 25;63(11):1122. PMID: 23954343.
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360(9346):1623-30. doi: 10.1016/s0140-6736(02)11600-x. PMID: 12457784.
Yourman LC, Cenzer IS, Boscardin WJ, Nguyen BT, Smith AK, Schonberg MA, et al. Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis. JAMA Intern Med. 2021;181(2):179-185. doi: 10.1001/jamainternmed.2020.6084. PMID: 33196766; PMCID: PMC7670393.
Holmes HM, Min LC, Yee M, Varadhan R, Basran J, Dale W, et al. Rationalizing prescribing for older patients with multimorbidity: considering time to benefit. Drugs Aging. 2013;30(9):655-66. doi: 10.1007/s40266-013-0095-7. PMID: 23749475; PMCID: PMC3755031.
Federal state statistics service. Life expectancy in Russian Federation. Av. at: https://rosinfostat.ru/prodolzhitelnost-zhizni/#i-6. 2019. [Russian: Федеральная служба государственной статистики. Ожидаемая продолжительность жизни в Российской Федерации. Доступно на: https://rosinfostat.ru/prodolzhitelnost-zhizni/#i-6. 2019]
Keeler E, Guralnik JM, Tian H, Wallace RB, Reuben DB. The Impact of Functional Status on Life Expectancy in Older Persons. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2010;65(7):727–33. DOI: 10.1093/gerona/glq029
Kotovskaya Y.V., Tkacheva O.N., Sergienko I.V. Lipid-Lowering Therapy for Primary Cardiovascular Prevention in Older Adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists. Kardiologiia. 2020;60(6):119–132. (Котовская Ю. В., Ткачева О. Н., Сергиенко И. В. Липидснижающая терапия для первичной профилактики у пациентов 75 лет и старше. Консенсус экспертов Российской ассоциации геронтологов и гериатров, Национального общества по изучению атеросклероза, Российского кардиологического общества, Ассоциации клинических фармакологов. Кардиология. 2020;60(6):119–132. doi.org/10.18087/cardio.2020.6.n1037
Zoungas S, Curtis A, Spark S, Wolfe R, McNeil JJ, Beilin L, et al. STAREE investigator group. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomized controlled trial in primary care (STAREE trial). BMJ Open. 2023;13(4):e069915. doi: 10.1136/bmjopen-2022-069915. PMID: 37012015; PMCID: PMC10083753.
Joseph J, Pajewski NM, Dolor RJ, Sellers MA, Perdue LH, Peeples SR, et al. PREVENTABLE Trial Research Group. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. J Am Geriatr Soc. 2023;71(6):1701-1713. doi: 10.1111/jgs.18312. Epub 2023 Apr 20. PMID: 37082807; PMCID: PMC10258159.
I. de Vries T, Cooney MT, Selmer R, Hageman S, Pennells S, Wood A et al. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42(25):2455-2467. doi: 10.1093/eurheartj/ehab312. PMID: 34120185; PMCID: PMC8248997.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022 Nov 7;43(42):4468. PMID: 34458905.
Dujovne CA, Chremos AN, Pool JL, Schnaper H, Bradford RH, Shear CL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med. 1991;91(1B):25S-30S. doi: 10.1016/0002-9343(91)90053-z.
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, Goldstein LB, et al.American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81. doi: 10.1161/ATV.0000000000000073. Erratum in: Arterioscler Thromb Vasc Biol. 2019 May;39(5):e158.
Senior JR. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 2014;37 Suppl 1(Suppl 1):S9-17. doi: 10.1007/s40264-014-0182-7.
Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367-79. doi: 10.1503/cmaj.1040752.
Bays H, Cohen DE, Chalasani N, Harrison SA. The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S47-57. doi: 10.1016/j.jacl.2014.02.011.
U.S. Food and Drug Administration. 2012: FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/drugs/drugsafety/ucm293101.htm. Accessed September 20, 2016.
Villani R, Navarese EP, Cavallone F, Kubica J, Bellanti F, Facciorusso A, et al. Risk of Statin-Induced Hypertransaminasemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mayo Clin Proc Innov Qual Outcomes. 2019;3(2):131-140. doi: 10.1016/j.mayocpiqo.2019.01.003.
Vell MS, Loomba R, Krishnan A, Wangensteen KJ, Trebicka J, Creasy KT, et al. Association of Statin Use with Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related Mortality. JAMA Netw Open. 2023;6(6):e2320222. doi: 10.1001/jamanetworkopen.2023.20222.
Abdallah M, Brown L, Provenza J, Tariq R, Gowda S, Singal AK. Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials. Ann Hepatol. 2022;27(6):100738. doi: 10.1016/j.aohep.2022.100738.
Li X, Sheng L, Liu L, Hu Y, Chen Y, Lou L. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis. BMC Gastroenterol. 2020;20(1):98. doi: 10.1186/s12876-020-01222-1.
Stokkeland K, Lageborn CT, Ekbom A, Höijer J, Bottai M, Stål P, et al. Statins and Angiotensin-Converting Enzyme Inhibitors are Associated with Reduced Mortality and Morbidity in Chronic Liver Disease. Basic Clin Pharmacol Toxicol. 2018;122(1):104-110. doi: 10.1111/bcpt.12844.
Becchetti C, Dirchwolf M, Schropp J, Magini G, Müllhaupt B, Immer F, et al. Swiss Transplant Cohort Study. Use of statins after liver transplantation is associated with improved survival: results of a nationwide study. Aliment Pharmacol Ther. 2022;56(7):1194-1204. doi: 10.1111/apt.17192.
Kandelouei T, Abbasifard M, Imani D, Aslani S, Razi B, Fasihi M, et al. Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mediators Inflamm. 2022;8732360. doi: 10.1155/2022/8732360.
Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017;120(1):229-243. doi: 10.1161/CIRCRESAHA.116.308537. Erratum in: Circ Res. 2018 Sep 28;123(8):e20.
Cho Y, Rhee H, Kim YE, Lee M, Lee BW, Kang ES, et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). BMC Med. 2022;20(1):93. doi: 10.1186/s12916-022-02288-2.]
Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? World J Hepatol. 2022;14(1):119-139. doi: 10.4254/wjh.v14.i1.119.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Fibrates. 2017 Jan 24. PMID: 31643229.
Musazadeh V, Karimi A, Malekahmadi M, Ahrabi SS, Dehghan P. Omega-3 polyunsaturated fatty acids in the treatment of non-alcoholic fatty liver disease: An umbrella systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2023;50(5):327-334. doi: 10.1111/1440-1681.13750.
Guedeney P, Giustino G, Sorrentino S, Claessen BE, Camaj A, Kalkman DN, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2019;ehz430. doi: 10.1093/eurheartj/ehz430.
Ioannou GN, Lee SP, Linsley PS, Gersuk V, Yeh MM, Chen YY, et al. Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol. Hepatol Commun. 2022;6(4):780-794. doi: 10.1002/hep4.1858.
Ebenezer O, Comoglio P, Wong GK, Tuszynski JA. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia. Int J Mol Sci. 2023;24(4):4019. doi: 10.3390/ijms24044019.
Muhandiramge J, Zalcberg JR, van Londen GJ, Warner ET, Carr PR, Haydon A, Orchard SG. Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology. Curr Oncol Rep. 2022;24(11):1579-1592. doi: 10.1007/s11912-022-01309-w. Epub 2022 Jul 7. PMID: 35796941; PMCID: PMC9606033.
Wang Z, Li J. Lipoprotein(a) in patients with breast cancer after chemotherapy: exploring potential strategies for cardioprotection. Lipids Health Dis. 2023;22(1):157. doi: 10.1186/s12944-023-01926-9. PMID: 37736722; PMCID: PMC10515253
Li Y, Wu S, Zhao X, Hao S, Li F, Wang Y, Liu B, Zhang D, Wang Y, Zhou H. Key events in cancer: Dysregulation of SREBPs. Front Pharmacol. 2023;14:1130747. doi: 10.3389/fphar.2023.1130747. PMID: 36969840; PMCID: PMC10030587
Dong S, Yu J, Chen X, Shen K. Association of serum lipid levels and clinical outcomes in early breast cancer patients. Ther Adv Med Oncol. 2023;15:17588359231177004
Sharma M, Tuaine J, McLaren B, Waters DL, Black K, Jones LM, et al. Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells. PLoS One. 2016;11(1):e0148049. doi: 10.1371/journal.pone.0148049. PMID: 26807857; PMCID: PMC4726544.
Heiston EM, Hundley WG. Statins for Cardiac and Vascular Protection During and After Cancer Therapy. Curr Oncol Rep. 2022;24(5):555-561. doi: 10.1007/s11912-022-01212-4. Epub 2022 Feb 24. PMID: 35199294.
Khazaaleh S, Sarmini MT, Alomari M, Al Momani L, El Kurdi B, Asfari M, et al. Statin Use Reduces the Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis and Systematic Review. Cureus. 2022;14(7):e27032. doi: 10.7759/cureus.27032. PMID: 35989795; PMCID: PMC9388192.
Jaiswal V, Agrawal V, Ang SP, Saleeb M, Ishak A, Hameed M, et al. Post-diagnostic statin use and its association with cancer recurrence and mortality in breast cancer patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2023;9(8):731-740. doi: 10.1093/ehjcvp/pvad057. PMID: 37562940.
Iakobishvili Z, Hasin T, Klempfner R, Shlomo N, Goldenberg I, Brenner R, et al. Association of Bezafibrate Treatment with Reduced Risk of Cancer in Patients With Coronary Artery Disease. Mayo Clin Proc. 2019;94(7):1171-1179. doi: 10.1016/j.mayocp.2018.10.026. PMID: 31272567
Han KT, Kim S. Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea. BMC Cancer. 2022;22(1):156. doi: 10.1186/s12885-022-09250-8. PMID: 35135497; PMCID: PMC8826710
Mohammadi KA, Brackin T, Schwartz GG, Steg PG, Szarek M, Manvelian G, et al. Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Med. 2023;12(16):16859-16868. doi: 10.1002/cam4.6310. Epub 2023 Jul 17. PMID: 37458138; PMCID: PMC10501297
Löfling LL, Støer NC, Andreassen BK, Ursin G, Botteri E. Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study. Breast Cancer Res. 2023;25(1):101. doi: 10.1186/s13058-023-01697-2. PMID: 37649039; PMCID: PMC10466817
Kim J, Nishimura Y, Kewcharoen J, Yess J. Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis. J Clin Med. 2021;10(16):3731. doi: 10.3390/jcm10163731. PMID: 34442027; PMCID: PMC8397057
Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244. Erratum in: Eur Heart J. 2023 May 7;44(18):1621. PMID: 36017568.
Cavaillès A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, et al. Comorbidities of COPD. Eur Respir Rev. 2013; 22(130):454-75. doi: 10.1183/09059180.00008612. PMID: 24293462; PMCID: PMC9639181.
Ambrosino P, Lupoli R, Iervolino S, De Felice A, Pappone N, Storino A, et al. Clinical assessment of endothelial function in patients with chronic obstructive pulmonary disease: a systematic review with meta-analysis. Intern Emerg Med. 2017; 12(6):877-885. doi: 10.1007/s11739-017-1690-0. Epub 2017 Jun 7. PMID: 28593450.
Fruchter O, Yigla M, Kramer MR. Lipid profile and statin use: the paradox of survival after acute exacerbation of chronic obstructive pulmonary disease. Am J Med Sci. 2015; 349(4):338-43. doi: 10.1097/MAJ.0000000000000435. PMID: 25719977.
Zhu Z, Wang X, Li X, Lin Y, Shen S, Liu CL, et al. International COPD Genetics Consortium; Boezen HM, Camargo CA Jr, Cho MH, Christiani DC. Genetic overlap of chronic obstructive pulmonary disease and cardiovascular disease-related traits: a large-scale genome-wide cross-trait analysis. Respir Res. 2019; 20(1):64. doi: 10.1186/s12931-019-1036-8. PMID: 30940143; PMCID: PMC6444755.
Citgez E, van der Palen J, Koehorst-Ter Huurne K, et al. Statins and morbidity and mortality in COPD in the COMIC study: a prospective COPD cohort study. BMJ Open Respir Res. 2016 Jun 17; 3(1):e000142. doi: 10.1136/bmjresp-2016-000142. PMID: 27403321; PMCID: PMC4932311.
Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther. 2013 Apr; 26(2):212-7. doi: 10.1016/j.pupt.2012.10.008. Epub 2012 Nov 7. PMID: 23142156.
Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev. 2009; 18(114):222-32. doi: 10.1183/09059180.00005309. PMID: 20956147.
Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J, Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015; 70(1):33-40. doi: 10.1136/thoraxjnl-2014-205795. Epub 2014 Oct 27. PMID: 25349333.
Lu Y, Chang R, Yao J, Xu X, Teng Y, Cheng N. Effectiveness of long-term using statins in COPD - a network meta-analysis. Respir Res. 2019; 20(1):17. doi: 10.1186/s12931-019-0984-3. PMID: 30674312; PMCID: PMC6343315.
Wang G, Shang W, Ren Y, Liu S, Ren X, Wei S, et al. Benefits of statins in chronic obstructive pulmonary disease patients with pulmonary hypertension: A meta-analysis. Eur J Intern Med. 2019; 70:39-42. doi: 10.1016/j.ejim.2019.09.009. Epub 2019 Oct 31. PMID: 31679886.
Chen YY, Li TC, Li CI, Lin SP, Fu PK. Statins Associated with Better Long-Term Outcomes in Aged Hospitalized Patients with COPD: A Real-World Experience from Pay-for-Performance Program. J Pers Med. 2022; 12(2):299. doi: 10.3390/jpm12020299. PMID: 35207787; PMCID: PMC8877141.
Franco D, Henao Y, Monsalve M, Gutiérrez F, Hincapie J, Amariles P. Interacciones medicamentosas de agentes hipolipemiantes: Aproximación para establecer y valorar su relevancia clínica. Revisión estructurada. Farm Hosp. 2013;37(6):539-557. doi:10.7399/FH.2013.37.6.1077
Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94(9):1140-6. doi: 10.1016/j.amjcard.2004.07.080. PMID: 15518608.
Christensen MM, Haastrup MB, Øhlenschlæger T et al. Interaction potential between clarithromycin and individual statins—A systematic review. Basic Clin Pharmacol Toxicol. 2020;126(4):307-317. doi: 10.1111/bcpt.13343. Epub 2019 Nov 8. PMID: 31628882.
Calza L. Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics. Drug Healthc Patient Saf. 2009;1:25-33. doi: 10.2147/dhps.s4928.
Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80(6):565-81. doi: 10.1016/j.clpt.2006.09.003. PMID: 17178259.
Neuvonen PJ. Drug interactions with HMG-CoA reductaseinhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs. 2010 Mar;11(3):323-32.
Caro L, Prueksaritanont T, Fandozzi C et al. Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults. Clin Drug Investig. 2021;41(2):133-147. doi: 10.1007/s40261-020-00974-8. PMID: 33527237.
Ahmadi Y, Karimian R, Panahi Y. Effects of statins on the chemoresistance—The antagonistic drug-drug interactions versus the anti-cancer effects. Biomedicine & Pharmacotherapy. 2018;108:1856-1865. doi: 10.1016/j.biopha.2018.09.122. Epub 2018 Oct 23. PMID: 30372891.
Franssen R, Vergeer M, Stroes ES, Kastelein JJ. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab. 2009;11(2):89-94. doi: 10.1111/j.1463-1326.2008.00917.x. Epub 2008 Jun 1. PMID: 18518891.
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2024 Г. П. Арутюнов, М. В. Ежов, А. С. Алиева, И. И. Шапошник, Я. А. Орлова, Н. А. Козиолова, Е. И. Тарловская, Н. Ю. Григорьева, А. И. Чесникова
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
